AVB 114
Alternative Names: Autologous mesenchymal stromal cell coated fistula plug - Avobis Bio; AVB-114; MSC-AFPLatest Information Update: 11 Nov 2025
At a glance
- Originator Mayo Clinic; W. L. Gore & Associates
- Developer Avobis Bio; Mayo Clinic
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Rectal fistula
- Phase I Rectovaginal fistula
- Research Wounds
Most Recent Events
- 11 Nov 2025 Early research in Wounds in USA (Implant), prior to November 2025 (Avobis Bio pipeline, November 2025)
- 11 Nov 2025 Phase-I clinical trials in Rectovaginal fistula (Treatment-experienced) (Implant), prior to November 2025 (Avobis Bio pipeline, November 2025)
- 11 Nov 2025 Adverse events and efficacy data from a phase I trial in Rectovaginal fistula released by Avobis Bio